Will new antimicrobials overcome resistance among Gram-negatives?

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 10, 2011, Pages 909-922

  Bassetti, Matteo ^a   Ginocchio, Francesca ^b   Mikulska, Małgorzata ^b   Taramasso, Lucia ^b   Giacobbe, Daniele Roberto ^b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

ESBL; ESCAPE; MBL; new anti Gram negative compounds; new classes of antimicrobials

Indexed keywords

ACHN 490; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AN 3365; AN 3665; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AVIBACTAM; BAL 30376; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; BLI 489; CARBAPENEM DERIVATIVE; CB 182 804; CHIR 090; CLAVULANIC ACID; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; KB 001; LK 157; MBX AGENT; ME 1071; METALLO BETA LACTAMASE; MK 7655; MONOBACTAM DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; TAZOBACTAM; TIGECYCLINE; TP 434; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BINDING AFFINITY; BINDING SITE; DRUG PROTEIN BINDING; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION CONTROL; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-LACTAMASES; CARBAPENEMS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INDOLES; INFECTION CONTROL; MICROBIAL SENSITIVITY TESTS; MONOBACTAMS; POLYMYXINS; PROTEIN SYNTHESIS INHIBITORS;

EID: 80053627057     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.107     Document Type: Review

References (94)

1. Kallen AJ, Srinivasan A. Current epidemiology of multidrug-resistant Gram-negative bacilli in the United States. Infect. Control Hosp. Epidemiol. 31(Suppl. 1), S51-S54 (2010
2. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 13, pii: 19045 (2008
3. Rodloff AC, Leclercq R, Debbia EA, Canton R, Oppenheim BA, Dowzicky MJ. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clin. Microbiol. Infect. 14(4), 307-314 (2008 (Pubitemid 351356520)
4. Maragakis LL. Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit. Care Med, 38(Suppl. 8), S345-S351 (2010
5. Peterson LR. Bad bugs, no drugs: No ESCAPE revisited. Clin. Infect. Dis. 49(6), 992-993 (2009). 6 Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob. Agents Chemother. 52(3), 813-821 (2008
6. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: A pandemic, multiresistant, community-associated strain. J. Antimicrob. Chemother. 66(1), 1-14 (2010
7. Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against Gram-negative bacteria collected in the United States. Clin. Ther. 32(4), 766-779 (2010
8. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46(2), 155-164 (2008 (Pubitemid 351269151)
9. Infectious Diseases Society of America. The 10 × '20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50(8), 1081-1083 (2010
10. Schaack S, Gilbert C, Feschotte C. Promiscuous DNA: Horizontal transfer of transposable elements and why it matters for eukaryotic evolution. Trends Ecol. Evol. 25(9), 537-546 (2010
11. Munoz-Price LS, Quinn JP. The spread of Klebsiella pneumoniae carbapenemases: A tale of strains, plasmids, and transposons. Clin. Infect. Dis. 49(11), 1739-1741 (2009
12. Brakhage AA, Al-Abdallah Q, Tüncher A, Spröte P. Evolution of b-lactam biosynthesis genes and recruitment of trans-acting factors. Phytochemistry 66(11), 1200-1210 (2005 (Pubitemid 40793874)
13. Rawat D, Nair D. Extended-spectrum b-lactamases in Gram negative bacteria. J. Glob Infect. Dis. 2(3), 263-274 (2010
14. Walsh TR. Emerging carbapenemases: A global perspective. Int. J. Antimicrob. Agents. 36(Suppl. 3), S8-S14 (2010
15. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum b-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. J. Antimicrob. Chemother. 60(5), 913-920 (2007 (Pubitemid 47617735)
16. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for b-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39(6), 1211-1233 (1995
17. Ambler RP. The structure of b-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 289(1036), 321-331 (1980
18. Thomson KS. Extended-spectrum-b-lactamase, AmpC, and carbapenemase issues. J. Clin. Microbiol. 48(4), 1019-1025 (2010
19. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9(4), 228-236 (2009
20. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect. Dis. 10(9), 597-602 (2010
21. Nordmann P, Poirel L, Toleman MA et al. Does broad-spectrum b-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteriâJ. Antimicrob. Chemother. 66(4), 689-692 (2011
22. Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: Mechanisms, frequency and treatment options. Drug Resist. Update 13(4-5), 132-138 (2010
23. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N. Engl. J. Med. 358(12), 1271-1281 (2008
24. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22(4), 582-610 (2009
25. Poulakou G, Kontopidou FV, Paramythiotou E et al. Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens. J. Infect. 58(4) 273-284 (2009
26. Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb. Drug Resist. 13(1), 1-6 (2007 (Pubitemid 46833752)
27. Drlica K, Malik M. Fluoroquinolones: Action and resistance. Curr. Top. Med. Chem. 3(3), 249-282 (2003
28. Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria-a description of the action, resistance mechanism, and nosocomial battleground. J. Biomed. Sci. 15(1), 5-14 (2008 (Pubitemid 350215830)
29. Dozzo P, Moser HE. New aminoglycoside antibiotics. Expert Opin. Ther. Pat. 20(10), 1321-1341 (2008
30. Eschenburg S, Priestman M, Schonbrunn E. Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamineenolpyruvyltransferase (MurA) is essential for product release. J. Biol. Chem. 280(5) 3757-3763 (2005 (Pubitemid 40223844)
31. Kobayashi S, Kuzuyama T, Seto H. Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coli. Antimicrob. Agents Chemother. 44(3), 647-650 (2010
32. Bassetti M, Righi E, Viscoli C. Novel b-lactam antibiotics and inhibitor combinations. Expert Opin. Investig. Drugs. 17(3), 285-296 (2008 (Pubitemid 351578181)
33. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46(5), 647-655 (2008 (Pubitemid 351321545)
34. El Solh A. Ceftobiprole: A new broad spectrum cephalosporin. Expert Opin. Pharmacother. 10(10), 1675-1686 (2009
35. Nannini EC, Stryjewski ME, Corey GR. Ceftaroline for complicated skin and skin-structure infections. Expert Opin. Pharmacother. 11(7), 1197-1206 (2010
36. Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including b-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(6), 2360-2366 (2009
37. Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis. 51(6), 641-650 (2010
38. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60(2), 300-311 (2007 (Pubitemid 47243878)
39. Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG. In vitro Activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Antimicrob. Agents Chemother. 55(6), 2837-2846 (2011
40. Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A. Activity of a new cephalosporin, CXA-101 (FR264205), against b-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 54(3), 1213-1217 (2010
41. Brown NP, Pillar CM, Sahm DF, Alluru V, Grover P, Ge Y. Activity profile of CXA-101 and CXA-101/tazobactam against target Gram-positive and Gram-negative pathogens. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009.
42. Ge Y, Whitehouse MJ, Friedland I, Talbot GH. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob. Agents Chemother. 54(8), 3427-3431 (2010). 44 Titelman E, Karlsson IM, Ge Y, Giske CG. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 70(1), 137-141 (2011
43. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement (June 2010 Update) M100-S20-U. CLSI, Wayne, PA, USA (2010
44. Bassetti M, Nicolini L, Esposito S, Righi E, Viscoli C. Current status of newer carbapenems. Curr. Med. Chem. 16(5), 564-575 (2009
45. Chahine EB, Ferrill MJ, Poulakos MN. Doripenem: A new carbapenem antibiotic. Am. J. Health Syst. Pharm. 67(23), 2015-2024 (2010
46. Betriu C, Gomez M, Lopez-Fabal F, Culebras E, Rodríguez-Avial I, Picazo JJ. Activity of doripenem against extended-spectrum b-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates. Eur. J. Clin. Microbiol. Infect. Dis. 29(9), 1179-1181 (2010
47. Queenan AM, Shang W, Flamm R, Bush K. Hydrolysis and inhibition profiles of b-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob. Agents Chemother. 54(1), 565-569 (2010
48. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit. Care Med. 36(4), 1089-1096 (2008 (Pubitemid 351482655)
49. Jia B, Lu P, Huang W et al. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy 56(4), 285-290 (2010
50. Gomi K, Fujimura S, Fuse K et al. Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007. J. Infect. Chemother. 17(2), 200-206 (2011
51. Fukushima Y, Fukushima F, Kamiya K et al. Relation between the antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa from respiratory specimens and antimicrobial use density (AUD) from 2005 through 2008. Intern. Med. 49(14), 1333-1340 (2010
52. Fujimura S, Nakano Y, Sato T, Shirahata K, Watanabe A. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa. J. Infect. Chemother. 13(3), 147-150 (2007 (Pubitemid 47012495)
53. Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T. Potent In vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52(8), 2849-2854 (2008
54. Livermore DM, Mushtaq S, Warner M. Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. J. Antimicrob. Chemother. 64(2), 330-335 (2009
55. Goa KL, Noble S. Panipenem/betamipron. Drugs 63(9), 913-925, discussion 926 (2003 (Pubitemid 36543086)
56. Yoshida S, Koga T, Kakuta M et al. In-vitro activity of panipenem against clinical isolates in 2006. Jpn J. Antibiot. 61(1), 1-17 (2008). 59 Morrissey I, Biek D, Janes R. ME1036, a novel carbapenem, with enhanced activity against clinical isolates causing bacteraemic community-acquired pneumonia. J. Antimicrob. Chemother. 64(1), 209-210 (2009
57. Russo TA, Page MG, Beanan JM et al. In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J. Antimicrob. Chemother. 66(4), 867-873 (2011
58. Page MG, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. Antimicrob. Agents Chemother. 54(6), 2291-2302 (2010
59. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int. J. Med. Microbiol. 300(6), 371-379 (2010
60. Weiss WJ, Petersen PJ, Murphy TM et al. In vitro and in vivo activities of novel 6-methylidene penems as b-lactamase inhibitors. Antimicrob. Agents Chemother. 48(12), 4589-4596 (2004 (Pubitemid 39577658)
61. Bebrone C, Lassaux P, Vercheval L et al. Current challenges in antimicrobial chemotherapy: Focus on b-lactamase inhibition. Drugs 70(6), 651-679 (2010
62. Petersen PJ, Jones CH, Venkatesan AM, Bradford PA. Efficacy of piperacillin combined with the penem b-lactamase inhibitor BLI-489 in murine models of systemic infection. Antimicrob. Agents Chemother. 53(4), 1698-1700 (2009
63. Shahid M, Sobia F, Singh A et al. b-lactams and b-lactamase-inhibitors in current- or potential-clinical practice: A comprehensive update. Crit. Rev. Microbiol. 35(2), 81-108 (2009
64. Ruzin A, Petersen PJ, Jones CH. Resistance development profiling of piperacillin in combination with the novel {b}-lactamase inhibitor BLI-489. J. Antimicrob. Chemother. 65(2), 252-257 (2010
65. Paukner S, Hesse L, Prezelj A, Solmajer T, Urleb U. In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {b}-lactamase inhibitor. Antimicrob. Agents Chemother. 53(2), 505-511 (2009
66. Jamieson CE, Lambert PA, Simpson IN. In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against Gram-positive and Gram-negative organisms. Antimicrob. Agents Chemother. 47(8), 2615-2618 (2003 (Pubitemid 36919467)
67. Bowker KE, Noel AR, Walsh TR, Rogers CA, MacGowan AP. Pharmacodynamics of ceftazidime plus the serine b-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 b-lactamases. Antimicrob. Agents Chemother. 48(11), 4482-4484 (2004 (Pubitemid 39434924)
68. Lagacé-Wiens PR, Tailor F, Simner P et al. Activity of NXL104 in combination with b-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum b-lactamases and class C b-lactamases. Antimicrob. Agents Chemother. 55(5), 2434-2437 (2011
69. Curcio D. Activity of a novel combination against multidrug-resistant nonfermenters: Ceftazidime plus NXL104. Expert Rev. Anti Infect. Ther. 9(2), 173-176 (2011
70. Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. Activity of chequerboard combinations of ceftaroline and NXL104 versus b-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 65(7), 1428-1432 (2010
71. Melchers R, Mavridou E, Van Mil A, Motyl MR, Mouton JW. In vitro activity of imipenem alone and in combination with MK-7655: A new b-lactamase inhibitor. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
72. Mavridou E, Melchers R, Van Mil A, Mangin E, Mouton JW. Pharmacodynamics of imipenem in combination with MK-7655, a b-lactamase inhibitor, in the neutropenic mouse thigh model. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010. 76 Hirsch EB, Ledesma KR, Chang KT, Motyl MR, Tam VH. In vitro activity of MK-7655 in combination with imipenem (IPM) against carbapenem resistant Gram-negative bacteria. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
73. Maltezou HC. Metallo-b-lactamases in Gram-negative bacteria: Introducing the era of pan-resistancê Int. J. Antimicrob. Agents. 33(5), 405, e1-e7 (2009
74. Livermore DM, Mushtaq S, Warner M. Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J. Antimicrob. Chemother. 65(11), 2382-2395 (2010
75. Page MG, Dantier C, Desarbre E, Gaucher B, Gebhardt K, Schmitt-Hoffmann A. In vitro and in vivo properties of BAL30376, a b-lactam and dual b-lactamase inhibitor combination with enhanced activity against Gram-negative bacilli that express multiple b-lactamases. Antimicrob. Agents Chemother. 55(4), 1510-1519 (2011
76. Ishii Y, Eto M, Mano Y, Tateda K, Yamaguchi K. In vitro potentiation of carbapenems with ME1071, a novel metallo-b-lactamase inhibitor, against metallo-b-lactamase- producing Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 54(9), 3625-3629 (2010
77. Sutcliffe J, Ronn M, Leighton A, Sprenger C. Phase 1 single ascending dose study of a broad-spectrum fluorocycline, TP-434. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
78. Talbot GH. The antibiotic development pipeline for multidrug-resistant Gram-negative bacilli: Current and future landscapes. Infect. Control Hosp. Epidemiol. 31(Suppl. 1), S55-S58 (2010
79. Livermore DM, Mushtaq S, Warner M et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66(1), 48-53 (2011
80. Landman D, Kelly P, Bäcker M et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J. Antimicrob. Chemother. 66(2), 332-334 (2011
81. Landman D, Babu E, Shah N et al. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J. Antimicrob. Chemother. 65(10), 2123-2127 (2011
82. Sader HS, Rhomberg PR, Jones RN. Antimicrobial activity of a novel polymyxin analog (CB-182,804) tested against clinical strains of Gram-negative bacilli, including colistin-resistant organisms. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
83. Opperman TJ, Houseweart C, Williams JD, Peet NP, Moir DT, Bowlin TL. The mechanism of antibacterial action of novel bis-indole antibiotics. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
84. Butler MM, Williams JD, Peet NP et al. Comparative in vitro activity profiles of novel bis-indole antibacterials against Gram-positive and Gram-negative clinical isolates. Antimicrob. Agents Chemother. 54(9), 3974-3977 (2010
85. Hernandez V, Akama T, Alley M et al. Discovery and mechanism of action of AN3365: A novel boron containing antibacterial agent in clinical development for Gram-negative infections. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
86. Biedenbach DJ, Mendes RE, Alley MRK, Sader HS, Jones R. Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against non-fermentative Gram-negative bacilli. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
87. Bouchillon S, Hoban D, Hackel M, Butler D, Demarsch P, Alley D. In vitro activities of AN3365: A novel boron containing protein synthesis inhibitor and other antimicrobial agents against anaerobes and Neisseria gonorrhoeae. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
88. Freund YR, Liu L, Alley MRK et al. Murine pharmacokinetics and in vivo Gram-negative activity of AN3365: A novel boron-containing protein synthesis inhibitor. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
89. Mansoor UF, Vitharana D. Reddy PA et al. Design and synthesis of potent Gram-negative specific LpxC inhibitors. Bioorg Med. Chem. Lett. 21(4), 1155-1161 (2011
90. Ippolito J, Wang D, Chen S et al. Novel antibiotic classes to treat Gram-negative infections. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009.
91. Peters BM, Shirtliff ME, Jabra-Rizk MA. Antimicrobial peptides: Primeval molecules or future drugŝ PloS Pathog. 6(10), e1001067 (2010
92. Vila-Farres X, Garcia-De La Maria C, Giralt E, Vila J. In vitro activity of mastoparan against colistin-susceptible and resistant Acinetobacter baumannii. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
93. Baer M, Sawa T, Flynn P et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect. Immun. 77(3), 1083-1090 (2009
94. Page MG, Heim J. Prospects for the next anti-Pseudomonas drug. Curr. Opin. Pharmacol. 9(5), 558-565 (2009).